生物芯片技术研究进展

生物芯片主要包括基因芯片、蛋白质芯片、组织芯片等。利用生物芯片技术可以从整个基因组的水平上对基因进行快速分析、筛选。本文主要概述了生物芯片技术的最新研究进展及在各个领域内的应用 ,并对生物芯片技术面临的挑战以及未来的发展方向作了讨论。     

生物芯片技术及其在基础生物科学研究中的应用

回顾了生物芯片的发展历史,重点介绍了生物芯片技术的两大技术基础：分子生物技术和微细加工生物技术;阐述了生物芯片技术的核心内容,总结了生物芯片的三大类型,并对生物芯片技术在生命科学基础研究中的应用进行了深入探讨和展望。     

超声微泡介导VEGF基因转染治疗缺血性疾病研究进展

："治疗性血管新生" 是利用外源性血管生长因子或基因促进缺血部位新生血管形成,达到改善缺血部位血液供应而起到治 疗的目的,该方法为缺血性疾病的治疗提供了新的思路。目前研究的多种与血管生成相关的因子中,血管内皮生长因子（Vascular Endothelial Growth Factor,VEGF）是公认的最具特异性且作用最强的促进血管生长因子。但由于外源性血管生长因子重组蛋白在 体内半衰期短,试验中难以长时间持续给药起到刺激新血管生成及成熟的作用。研究表明通过超声破坏微泡技术可使基因转染 的靶细胞持续表达该基因。因此,应用超声靶向微泡破坏技术使VEGF 基因在缺血部位持续表达,可起到治疗性血管新生的作 用。本文将就超声微泡介导VEGF基因转染治疗缺血性疾病研究进展进行综述。     

生物芯片技术专利计量研究

生物芯片的研究始于80年代中期,是现代生物学技术与计算机等其他领域高新技术相结合的产物,在基因、蛋白质等生命领域研究中起到至关重要的作用。本文对Derwent数据库中收录的有关生物芯片的专利数据进行分析,从多个专利计量指标入手,分析生物芯片技术领域的研究现状及发展动态。通过计量研究发现生物芯片技术领域自21世纪以来发展迅猛,发达国家占据主动,而我国在该领域的科研水平也处于世界前列。     

t—PA cDNA基因转移与基因治疗

组织型纤溶酶原激活剂（ｔ－ＰＡ）能够特异、高效地溶解血栓,在纤溶系统中起着重要作用,ｔ－ＰＡ与其抑制物（ＰＡＩ）平衡失调,可导致多种疾病的发生。基因转移技术使外源ｔ－ＰＡ ｃＤＮＡ成功地在血管内皮细胞中得以表达,为防治以血栓形成为主要病理变化的血管性疾病开辟了广阔的前景。     

基因芯片技术能发展和应用

基因芯片技术是以基因序列为分析对象的生物芯片．是技术最成熟、最早进入应用和实现商业化的生物芯片。基因芯片是把大量已知序列探针集成在同一个基片上,经过标记的靶核苷酸序列与芯片特定位点上的探针杂交,通过检测杂交信号,对细胞或组织中大量的基因信息进行检测与分析。1991年Affymetfix公司的Fodor等人应用光刻技术研发了世界上第一张基因芯片。     

生物芯片技术及其在疾病诊断和疫苗设计中的应用

生物芯片技术是一项潜力巨大的技术,即将成为新世纪医学、生物学研究领域的有力工具。本文简要叙述了生物芯片技术的原理与方法,并对生物芯片技术在疾病诊断及疫苗与药物设计中的应用作了概要介绍。     

生物芯片技术与食品分析

生物芯片检测技术是一种全新的微量分析技术。本文综述了生物芯片基本技术流程包括方阵构建、样品制备、化学反应和结果检测 ;探讨了生物芯片技术在食品分析中的应用前景 ;分析了生物芯片应用的技术障碍 ,旨在为生物芯片应用发展提供理论基础。     

生物芯片研究进展

生物芯片是便携式生物化学分析器的核心技术。通过对微加工获得的微米结构作生物化学处理能使成千上万个与生命相关的信息集成在一块厘米见方的芯片上。采用生物芯片可进行生命科学和医学中所涉及的各种生物化学反应,从而达到对基因、抗原和活体细胞等进行测试分析的目的。生物芯片发展的最终目标是将从样品制备、化学反应到检测的整个生化分析过程集成化以获得所谓的微型全分析系统（ｍｉｃｒｏｔｏｔａｌａｎａｌｙｔｉｃａｌｓｙｓ－ｔｅｍ）或称缩微芯片实验室（ｌａｂｏｒａｔｏｒｙｏｎａｃｈｉｐ）。生物芯片技术的出现将会给生命科学、医学、化学、新药开发、生物武器战争、司法鉴定、食品和环境卫生监督等领域带来一场革命。本文阐述了生物芯片技术在加工制备、功能和应用方面的近期研究进展。     

生物芯片技术的发展与应用

生物芯片的概念于20世纪90年代初期提出．之后便涌现出大量关于生物芯片的报道．尤其是进入21世纪,随着生物芯片技术所涉及的物理、化学、生物等技术的快速发展,生物芯片技术取得了很好的进展．技术平台日益稳定．开发的产品越来越多,已经在生命科学,药物研发,临床疾病检测与诊断．环境,农林业等领域中得到了广泛的应用。本文对生物芯片技术的原理、制备、试验设计和应用等方面进行了简要的综述。     

Gene functional similarity search tool (GFSST)

Background  

With the completion of the genome sequences of human, mouse, and other species and the advent of high throughput functional genomic research technologies such as biomicroarray chips, more and more genes and their products have been discovered and their functions have begun to be understood. Increasing amounts of data about genes, gene products and their functions have been stored in databases. To facilitate selection of candidate genes for gene-disease research, genetic association studies, biomarker and drug target selection, and animal models of human diseases, it is essential to have search engines that can retrieve genes by their functions from proteome databases. In recent years, the development of Gene Ontology (GO) has established structured, controlled vocabularies describing gene functions, which makes it possible to develop novel tools to search genes by functional similarity.     

The role of molecular genetic alterations in genes involved in folate and homocysteine metabolism in multifactorial diseases pathogenesis

The molecular genetic modifications in multiple genes involved in folate and homocysteine metabolism play the pivotal role in the development of hyperhomocysteinemia. Hyperhomocysteinemia is observed in 5% of patients worldwide and accompanies various multifactorial diseases, including neurodegenerative, autoimmune and vascular disorders and tumors. It should be noted that increased homocysteine level itself may point to some imbalance in the organism and represent a diagnostic marker of the development of some pathology. The present review describes the role of molecular-genetic modifications in one carbon metabolism accompanying different multifactorial diseases, including congenital birth defects, vascular disorders, diabetes, and hormone-dependent cancers such as breast and ovarian cancer. Data of the association between the SNPs in functionally significant genes involved in the one carbon metabolism and pathologies mentioned above were demonstrated. In addition, we firstly represent the data of the involvement of epigenetic factors (hypermethylation and miRNA) in regulation of these genes in multifactorial diseases. The section devoted to the role of molecular-genetic impairments in the genes involved in homocysteine metabolism associated with breast and ovarian cancer includes worldwide findings and our own results.     

皂苷类成分对血管内皮细胞功能的调节作用研究进展

血管内皮细胞在维持血管生理稳态中发挥了重要的作用,其功能障碍是动脉粥样硬化、冠心病、脑卒中、肿瘤等多种重大疾病发生发展的病理基础,调节血管内皮细胞功能是防治上述疾病的主要途径之一。大量研究表明,皂苷类成分可通过改善血管内皮功能达到治疗疾病的目的。综述了近年来报道的皂苷类成分调节血管内皮功能的研究进展,旨在为皂苷类成分作用机制的阐明和相关重大疾病的防治提供一定参考。     

The role of endothelial dysfunction and oxidative stress in cerebrovascular diseases

Cerebrovascular diseases (CBD) are one of the most dangerous complications of atherosclerosis. The clinical consequences of CBD deeply impact quality of life and the prognosis of patients. Atherosclerosis is the main cause of CBD development. Hypertension, dyslipidemia, diabetes, smoking, obesity, and other risk factors explain the higher CBD incidence in the general population, as they are able to anticipate the clinical expression of atherosclerosis. These risk factors are effectively able to promote endothelial dysfunction which is the premise for the early, clinical expression of atherosclerosis. The mechanisms by which risk factors can influence the occurrence of CBD are different and not fully understood. The inflammatory background of atherosclerosis can explain a great part of it. In particular, the oxidative stress may promote the development of vascular lesions by negatively influencing biochemical cellular processes of the endothelium, thus predisposing the vascular tree to morphological and functional damages. The aim of this narrative review is to evaluate the role of endothelial dysfunction and oxidative stress in CBD development.     

The prevalence of obesity-related hypertension and risk for new vascular events in patients with vascular diseases

Higher body weight is associated with an increased prevalence of vascular risk factors. Obesity leads to hypertension by various mechanisms, often referred to as obesity-related hypertension. Aim of the present study was to evaluate the prevalence and the vascular risk of the combination of obesity and hypertension in patients with vascular diseases. A cohort of patients with various clinical manifest vascular diseases (n = 4,868) was screened for vascular risk factors and followed (median follow-up 4.2 years) for the occurrence of vascular events (stroke, myocardial infarction, and vascular death). The prevalence of obesity was 18% (95% confidence interval (CI) 17-19%) and the prevalence of hypertension was 83% (95% CI 82-84%). The prevalence of the combination of obesity and hypertension was 16% (95% CI 15-17%). Patients with high blood pressure (BP) combined with a high weight (highest tertile systolic BP (SBP) in the highest tertile BMI) were not at higher risk for new vascular events (hazard ratios (HR) 1.29; 95% CI 0.89-1.88) or mortality (HR 1.18; 95% CI 0.81-1.73) compared to patients without high BP and high weight (patients in the lowest tertile of SBP in the lowest tertile of BMI). Patients with only high weight did not have an elevated risk either for vascular events (HR 1.34; 95% CI 0.91-1.98) or mortality (HR 1.22; 95% CI 0.81-1.83) compared to patients without high BP and high weight. The prevalence of the combination of hypertension and obesity is low in patients with vascular diseases and does not confer a higher risk for recurrent vascular diseases and mortality than each risk factor alone.     

Homocysteine,MTHFR gene polymorphisms, and cardio-cerebrovascular risk

Vascular diseases are commonly associated with traditional risk factors, but in the last decade scientific evidence has suggested that elevated plasma levels of homocysteine are associated with an increased risk of atherosclerosis and cardiovascular ischaemic events. Cardio- and cerebrovascular diseases are multifactorial, as their aetiopathogenesis is determined by genetic and environmental factors and by gene-gene and gene-environment interactions. Experimental studies have shown that many possible mechanisms are implicated in the pro-atherogenic effect of homocysteine. Hyperhomocysteinaemia may confer a mild risk alone, but it increases the risk of disease in association with other factors promoting vascular lesions. Variants in genes encoding enzymes involved in homocysteine metabolism, or depletion of important cofactors or substrates for those enzymes, including folate, vitamin B12 and vitamin B6, may result in elevated plasma homocysteine levels. Several studies have been performed to elucidate the genetic determinant of hyperhomocysteinaemia in patients with vascular disease, and the MTHFR 677C>T polymorphism is the one most extensively investigated. However, the lack of homogeneity in the data and the high number of factors influencing plasma homocysteine concentrations remain conflicting. Moreover, studies on the evaluation of therapeutic interventions in improving the atherogenic profile, lowering plasma homocysteine levels, and preventing vascular events, have shown inconsistent results, which are reviewed in this paper. More prospective, double-blind, randomized studies, including folate and vitamin B interventions, and genotyping for polymorphisms in genes involved in homocysteine metabolism, might better define the relationship between mild hyperhomocysteinaemia and vascular damage.     

Novel therapeutic approaches in utilizing platelet lysate in regenerative medicine: Are we ready for clinical use?

Hemoderivative materials are used to treat different diseases. These derivatives include platelet-rich plasma, serum, platelet gel, and platelet lysate (PL). Among them, PL contains more growth factors than the others and its production is inexpensive and easy. PL is one of the proper sources of platelet release factors. It is used in cells growth and proliferation and is a good alternative to fetal bovine serum. In recent years, the clinical use of PL has gained more appeal by scientists. PL is a solution saturated by growth factors, proteins, cytokines, and chemokines and is administered to treat different diseases such as wound healing, bone regeneration, alopecia, oral mucositis, radicular pain, osteoarthritis, and ocular diseases. In addition, it can be used in cell culture for cell therapy and tissue transplantation purposes. Platelet-derived growth factor, fibroblast growth factor, insulin-like growth factor, transforming growth factor β, and vascular endothelial growth factor are key PL growth factors playing a major role in cell proliferation, wound healing, and angiogenesis. In this paper, we scrutinized recent advances in using PL and PL-derived growth factors to treat diseases and in regenerative medicine, and the ability to replace PL with other hemoderivative materials.     

Blood filterability in ischemic heart disease

The aim of this paper is to test whether an alteration of blood flow in microcirculation and in particular of red cell deformability is present in myocardial ischaemia. To this end we determined by the method proposed by Reid and Dormandy (J. Clin. Pharmacol. 1976, 29, 855) whole-blood filterability in 23 patients with myocardial ischaemia, in 15 clinically healthy subjects and in 99 subjects without clinical evidence of ischemic pathology displaying one or more vascular risk factors. Blood filterability turned out to be significantly lower in cases of coronary diseases than in controls (p less than 0,001), while it was lower but not significantly so, than in subjects displaying risk factors. We conclude therefore that the presence of risk factors is enough important to be considered one of the fundamental elements (though non the only one) in causing the reduction of blood-filterability encountered in ischemic cardiopathology.     

Delivery of growth factor‐based therapeutics in vascular diseases: Challenges and strategies

Either cardiovascular or peripheral vascular diseases have become the major cause of morbidity and mortality worldwide. Recently, growth factors therapeutics, whatever administrated in form of exogenous growth factors or their relevant genes have been discovered to be an effective strategy for the prevention and therapy of vascular diseases, because of their promoting angiogenesis. Besides, as an alternative, stem cell‐based therapy has been also developed in view of their paracrine‐mediated effect or ability of differentiation toward angiogenesis‐related cells under assistance of growth factors. Despite of being specific and potent, no matter growth factors or stem cells‐based therapy, their full clinical transformation is limited from bench to bedside. In this review, the potential choices of therapeutic modes based on types of different growth factors or stem cells were firstly summarized for vascular diseases. The confronted various challenges such as lack of non‐invasive delivery method, the physiochemical challenge, the short half‐life time, and poor cell survival, were carefully analyzed for these therapeutic modes. Various strategies to overcome these limitations are put forward from the perspective of drug delivery. The expertised design of a suitable delivery form will undoubtedly provide valuable insight into their clinical application in the regenerative medicine.